Oral administration of Ipragliflozin
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Jun 1, 2016 → Mar 1, 2017
NCT ID
NCT02791035About Oral administration of Ipragliflozin
Oral administration of Ipragliflozin is a approved stage product being developed by Astellas Pharma for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02791035. Target conditions include Type 2 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02791035 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus